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Abstract
The neuropeptide melanin-concentrating hormone (MCH) plays a key role in energy 
maintenance by decreasing energy expenditure and stimulating feeding behavior. 
Furthermore, it is involved in diabetes, gut inflammation, sleep, depression, and cilia 
beat function. The biological function of MCH is mediated by two G-protein coupled 
receptors, MCH receptor 1 and 2 (MCHR1 and MCHR2). Since only the MCHR1 is func-
tional in rodents, the physiological importance of MCHR2 remains unknown due to the 
lack of appropriate animal models. The involvement of the MCHergic system in a variety 
of pathologies, especially endocrinological diseases, such as obesity and diabetes, makes 
it interesting as a new target to treat human disorders. Many pharmaceutical compa-
nies have pursued the development of MCHR1 antagonists for the treatment of obesity. 
Moreover, positron emission tomography (PET) tracers targeting the MCHR1 have been 
developed in order to gain a deeper understanding of the role and distribution of the 
MCHR1. As a high-end technique, PET allows noninvasive in vivo visualization and 
quantification of receptor systems, as well as monitoring and following hormone recep-
tor status and related pathologies. Therefore, a MCHR1 PET tracer could help to guide 
pharmacological intervention via the MCHR1.
Keywords: MCHR1, PET, imaging, tracer, antagonist
1. Introduction
Melanin-concentrating hormone (MCH) was first referenced as “melanophore-concentrating 
hormone” in studies examining the possible origin of a factor leading to lightning of fish skin 
color in 1955 [1]. Although speculations regarding the existence of such a factor date back 
to the 1930s—when studies of pigmentation changes in amphibians were performed [2]—
the isolation of MCH succeeded only in 1983 [3]. It was gained from the pituitary gland of 
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Figure 1. Structure of MCH and MCHR1.
the salmon and characterized as a cyclic 17-amino acid polypeptide with a cysteine-cysteine 
disulfide bond [3]. In teleost fish, MCH is synthesized as a preprohormone in the pituitary 
gland and is secreted into the circulation, where it acts as the opponent of melanocyte-stim-
ulating hormone (α-MSH) by lightning the skin color in response of the environmental back-
ground. This effect is due to the aggregation of pigment granules within melanophores [4, 5].
Several years after the discovery in fish, MCH was identified in mammalian brain, too. It was 
first isolated from rat hypothalamic fragments and characterized as a 19-amino acid peptide [6], 
which was found to be identical to human MCH [7] (structure shown in Figure 1). Generally, 
MCH is present in all groups of vertebrates from lampreys to humans and exhibits considerable 
structural coherence among different species [8]. MCH is derived by posttranslational cleavage 
from the C terminus of a 165 amino-acid precursor, pre-proMCH (ppMCH). The preprohor-
mone is also generating two additional peptides, neuropeptide-glutamic acid-isoleucine (NEI), 
and neuropeptide-glycine-glutamic acid (NGE). The gene encoding MCH is called Pmch [7].
In mammals, MCH is predominantly expressed in the lateral hypothalamus and zona incerta 
and projects broadly throughout the central nervous system (CNS) [9, 10]. Furthermore, it is 
also found in peripheral tissues, such as colonic epithelial cells [11], adipocytes [12], or beta-
cells of the islets of Langerhans [13]. Although it is expressed in human melanocytes too, it 
has not been shown to affect human pigmentation [14]. In mammals, MCH operates as a neu-
ropeptide, playing a key role in energy maintenance by decreasing energy expenditure and 
stimulating feeding behavior [15–17].
Initial efforts to identify a MCH receptor were based on binding assays by using radiola-
beled MCH. MCH-binding sites were detected in a variety of cells and in rat brain [18, 19]. 
However, the existence of the MCH receptor remained obscure until 1999, when it was found 
to be identical to the previously cloned orphan G protein-coupled receptor somatostatin-like 
clone 1 (SLC-1), which exhibited about 40% homology to the five somatostatin receptors in 
its hydrophobic domains. The first MCH receptor (MCHR1) was identified simultaneously 
by several groups using different pharmacological approaches [20–24]. MCHR1 is 353 amino 
acids long and has all hallmark features of the G protein-coupled receptors, including seven 
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Rat Human
Brain region
Hypothalamus ++ [23] +++ [29]
Thalamus +++ [30] ++ [29]
Hippocampus +++ [23] ++ [31]
Amygdala ++ [23] + [31]
Pons + [22] ++ [29]
Medulla oblongata ? ++ [29]
Substantia nigra ++ [23] ++ [32]
Nucleus accumbens +++ [23] ++ [33]
Locus coeruleus ++ [23] ?
Olfactory system +++ [23] ?
Cerebral cortex ++ [22] + [29]
Cerebellum ++ [34] + [29]
Peripheral tissues
Pituarity + [23] ++ [33]
Eye ++ [23] ?
Tongue + [23] ?
Sceletal muscle ++ [23] – [32]
Adipose tissue + [23] + [33]
Liver – [23] + [32]
Heart – [23] – [32]
Thymus ? – [32]
Spleen ? – [32]
Kidney – [23] – [32]
Adrenal + [35] + [31]
Testis + [36] + [32]
Ovary ++ [36] ++ [32]
Placenta ? – [32]
Prostate ? – [32]
Stomach ? – [33]
Pancreas + [37] + [13]
Colonic epithelial 
cells
? + [11]
+++, high abundance; ++, moderate abundance; +, low abundance; –, not detectable; ?, not investigated.
Table 1. Binding sites of MCH/MCHR1 mRNA distribution pattern.
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transmembrane helices, a DRY motif at the end of the third intracellular loop, and three 
potential glycosylation sites at the N-terminus [25] (structure shown in Figure 1).
Comparison of the human and the rodent receptors shows a high degree of conservation 
between species (human-rat 96% identity; human-mouse 95% identity), which is not unex-
pected knowing that the ligand structure is identical in human, rat, and mouse [25, 26].
Activation of MCHR1, which couples to multiple G proteins (G
i
, G
o
, and G
q
)
,
 leads to an increase 
in intracellular Ca2+ accumulation via stimulation of phospholipase C, lowered cyclic adenosine 
monophosphate levels (cAMP) via inhibition of adenylate cyclase, and stimulation of extracellu-
lar-signal-regulated kinase [27]. In the CNS, activation of these signaling pathways has diverse 
effects, ranging from changes in gene expression to modulation of ion channel activity [28].
MCHR1 is predominately expressed in the brain; besides, it is also found in moderate to weak 
concentration in other tissues. An overview of the widespread MCHR1 distribution is given 
in Table 1.
In 2001, a second MCH receptor (MCHR2) was identified with 340 amino acids of length [32, 
33, 38, 39]. The overall homology between the two MCH receptors is quite low; they share only 
38% identical amino acids. It also seems that the signal transduction mechanism of MCHR2 is 
limited to the G
q
 protein, resulting in increased intracellular Ca2+ levels. Its expression profile 
is similar to MCHR1, with the highest expression in the brain, notably in the frontal cortex, 
amygdala, hippocampus, nucleus accumbens, and putamen [38]. Low levels were found in 
the thalamus, hypothalamus, medulla oblongata, and no expression was found in the cerebel-
lum. Peripheral expression was shown in adipocytes, pancreas, prostate, and intestine [40]. 
MCHR2 is found to be a pseudogene in rodent species, but—interestingly—is known to be 
functional only in dogs, ferrets, rhesus monkeys, and humans [41]. Due to the lack of appro-
priate animal models, the physiological importance of MCHR2 remains unknown until now.
2. Physiological function of the MCHergic system
MCH plays a major role in energy homeostasis, e.g., the control of food intake, body weight, 
and metabolism [15–17]. It has been shown that MCH-deficient (MCH-KO) mice are leaner than 
wild-type mice and their body weight deficit is about 25% at 4 months of age. The decrease in 
body weight is the result of reduced food intake (hypophagia) and a slight increase in energy 
expenditure. Leptin levels are low, as would be expected in a lean mouse model. Otherwise, 
the mice appear to be normal, with normal levels of activity and normal fertility [42].
In contrast, MCH overexpressing (MCH-OE) mice developed—when placed on a high-fat 
diet—excessive obesity compared with wild-type mice. The reason, therefore, is that MCH-OE 
mice are hyperphagic. Furthermore, these animals had elevated blood glucose levels, signifi-
cant hyperinsulinemia, and islet cell hyperplasia [43]. Chronic infusion of MCH in mice repro-
duced the hyperphagic obese phenotype seen in the transgenic mice (MCH-OE mice) [17].
Considering the receptor, MCHR1 knockout (MCHR1-KO) mice are—when maintained 
at regular feed—lean and have a reduced fat mass. The leanness is due to hyperactivity, 
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increased energy expenditure, and altered metabolism. A dramatic 250% increase in run-
ning-wheel activity was reported [44]. Paradoxically, they were found to be hyperphagic 
compared with wild-type mice. This effect was interpreted as a compensatory response. 
When placed on a high-fat diet, they gain significantly less weight and are less suscepti-
ble to diet-induced obesity (DIO). Chronic infusion of MCH did not show any effects in 
MCHR1-KO mice [16].
Furthermore, MCH plays an important role in mediating the effects of leptin on energy 
homeostasis. Leptin is predominantly secreted from adipocytes and is referred as “adiposity 
signal,” circulating in proportion to body-fat content [45]. Leptin-deficient (ob/ob) mice are 
obese, hyperphagic, insulin resistant, and had significantly increased MCH expression [15].
Crossing the ob/ob mice to the MCH-KO mice caused a significant reduction in body weight 
with increased energy expenditure, thermogenesis, and locomotor activity. Further, they 
showed improved glucose homeostasis [46].
In MCHR1-KO mice, which were crossed with the ob/ob mice, body-fat mass decreased and 
locomotor activity increased. No differences in body weight, food intake, or energy expendi-
ture could be observed compared with the ob/ob mice. Despite being obese, MCHR1-KO ob/
ob mice had improved insulin sensitivity [47].
All these findings illustrate the central role of MCH in regulating energy homeostasis: 
MCH promotes the conservation of body energy and the loss of MCH function leads to 
leanness. Conservation of energy is also one of the main functions of sleep. Hence, it seems 
likely that MCH has also a function in sleep regulation. Several research groups described 
the role of MCH as a sleep promoter (reviewed by Torterolo et al. [48]). MCHergic neu-
rons project throughout the central nervous system, including areas involved in the con-
trol of sleep, such as the dorsal and median raphe nuclei. The fact the MCHergic neurons 
are active during sleep, especially during rapid eye movement (REM) sleep, indicates the 
MCH plays a critical role in the generation and maintenance of sleep. An increase in the 
duration of REM sleep is considered as an important biological marker for depression 
[49]. Furthermore, the expression of MCHR1 in serotonergic neurons, as well as MCHergic 
projections toward the limbic system, suggest a relevant role of MCH in the control of 
emotional states [50]. Several preclinical studies demonstrated the antidepressant and anx-
iolytic effects of MCHR1 antagonists (i.e. [51, 52]).
Furthermore, it has been shown that MCH contributes to maintain cerebrospinal fluid (CSF) 
homeostasis: MCHR1 is expressed in the ependymal cells of the third ventricle, where it is 
involved in the regulation of cilia beat frequency [53, 54]. This beating facilitates cerebrospinal 
fluid (CSF) circulation, which is crucial for brain function, as defects in ventricular cilia result 
in hydrocephalus. A lack of MCH receptor provokes a ventricular size increase as observed 
in MCHR1-KO mice. Brain penetrating MCHR1 antagonists may thus alter CSF flow, limiting 
their potential use as therapeutic agents.
Since both, MCH and MCHR1 are expressed in islets and clonal beta-cell lines [13], some 
peripheral effects of MCH were also observed. MCH has a direct effect on islet signaling 
pathways, insulin secretion, and insulin sensitivity [13]. As mentioned above, MCH-OE mice 
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have substantial hyperinsulinemia and islet hyperplasia that is out of proportion with their 
degree of obesity [43]. In contrast, MCH-KO mice have normal or improved glucose tolerance, 
despite having less insulin release in response to a glucose load [55]. Furthermore, MCH stim-
ulates leptin production in adipocytes, where the MCHR1 is present too [12]. MCH was also 
found to be a mediator of intestinal inflammation. MCH and MCHR1 mRNA expression are 
increased in human colitis. MCH-KO mice had a significant protection from induced colitis, 
suggesting that MCH has a proinflammatory role in the development of colitis [11]. Pmch and 
MCHR1 were also found in human immune cells. This may provide a link between allergic 
inflammation, asthma, and obesity [56, 57].
An overview of the multiple involvement of the MCHergic system is given in Figure 2.
3. Targeting the MCHR1
The involvement of the MCHergic system in a variety of pathologies, especially endocrinolog-
ical diseases such as obesity and diabetes, makes it interesting as a new target to treat human 
disorders. Since it has been shown that MCHR1 antagonists reduce body weight in rodents 
(reviewed by MacNeil [58]), several MCHR1 antagonists were developed in the last 15 years; 
some of them have entered clinical trials for the treatment of obesity [59], while some are in 
discussion of becoming anti-diabetic drugs [60].
The first functional, competitive MCHR1 antagonist was the 
D-
Ala11 analog of hMCH [61]. 
Subsequently, a series of analogs with antagonist activity were generated, such as Ac-(Ava9-10, 
Ava14-15)-hMCH(6-16)-NH
2
 (also known as PMC-3881-PI) [62]. However, peptide MCHR1 
antagonists are not able to cross the blood-brain barrier (BBB) and interact with the MCHR1 
in the CNS. Therefore, small molecule MCHR1 antagonists were developed. The first nonpep-
tide antagonist was T-226296 (Takeda), an orally active compound that demonstrated high 
affinity and selectivity to the MCHR1 (Ki = 5.5 nM) [63].
Screening of a G protein-coupled receptor-based compound library against the human 
MCHR1 in a functional assay measuring intracellular Ca2+ mobilization resulted in the 
Figure 2. Involvement of the MCHergic system.
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 discovery of a second nonpeptide antagonist, SNAP-7941 ((+)-methyl (4S)-3-{[(3-{4-[3-
(acetylamino)phenyl]-1-piperidinyl}propyl)amino]carbonyl}-4-(3,4-difluorophenyl)-
6-(methoxymethyl)-2-oxo-1,2,3,4-tetrahydro-5-pyrimidine carboxylate hydrochloride) 
(Synaptic/Lundbeck, Figure 3 (1)) [51]. SNAP-7941 has an excellent binding affinity 
(Kd = 0.18 nM) and selectivity (>1000-fold) to the MCHR1. In rat brain sections, binding 
of radiolabeled SNAP-7941 ([3H]SNAP-7941) was detected in the cerebral cortex, olfac-
tory tubercle, claustrum, piriform cortex, hippocampus, amygdala, caudate-putamen, 
accumbens nucleus, hypothalamus, dorsal raphe, and locus coerulus [51]. This distribution 
pattern parallels the widespread MCHR1 expression in the brain [30]. Further, systemic 
pretreatment with SNAP-7941 (10 mg/kg, intraperintoneal (i.p.)) inhibited the increase in 
food intake induced by intra-cerebroventricular (i.c.v.) injection of MCH (3 nmol). Rats 
treated with SNAP-7941 (10 mg/kg, i.p.) twice a day for seven days gained 26% less weight 
compared with their littermates. SNAP-7941 was also capable to decrease milk consump-
tion in satiated rats: 13% less milk consumption in rats treated with 3 mg/kg (i.p.), 41% 
with 10 mg/kg (i.p.), and 59% with 30 mg/kg (i.p.) compared with vehicle-treated rats. 
These results suggest that SNAP-7941 acts as an anorectic agent. To rule out that this ano-
rectic effect was due to malaise, a taste aversion study was performed, which confirmed 
that the anorectic effect of SNAP-7941 was not a result of malaise. In DIO rats, SNAP-
7941 (10 mg/kg, i.p., twice daily over four weeks) produced a sustained and consistent 
decrease in food consumption and body weight. This effect was reversible insofar as two 
weeks after the termination of the treatment, DIO rats previously treated with SNAP-7941 
showed an increase in body weight and food consumption. A toxic effect of SNAP-7941 as 
a causal role for reduction in food intake and weight gain was ruled out by blood tests of 
the hepatic and renal function of the drug treated rats [51]. All these findings render the 
MCHR1 a viable target for the treatment of obesity. Additionally to the reported anorectic 
effects, SNAP-7941 evinced antidepressant and anxiolytic properties. A single oral dose of 
SNAP-7941 (3, 10, and 30 mg/kg) significantly decreased the duration of immobility and 
increased the swimming time of rats in the forced-swim test. Unfamiliar male rats showed 
increased social interaction time after acute treatment with SNAP-7941. Finally, the high-
frequency vocalizations emitted from guinea pig pups separated from their mothers were 
significantly reduced after treatment with SNAP-7941 [51]. These anxiolytic effects were 
not supported by another group [64].
Figure 3. SNAP-7941 derivatives (1: SNAP-7941; 2: [11C]SNAP-7941; 3: [18F]FE@SNAP).
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Several other small molecule antagonists were developed from pharmaceutical com-
panies, e.g., ATC0065 and ATC0175 (Arena/Taisho collaboration) [65, 66], GW803430 
(GlaxoSmithKline) [67], SNAP 94847 (Synaptic/Lundbeck) [52], AMG-076 (Amgen) [68], and 
NGD-4715 (Neurogen) [69]. All these drugs are BBB-penetrating compounds, which is man-
datory to reduce body weight [70].
Due to medical need for oral anti-diabetics that give weight loss, a dual MCHR1 antagonist/
dipeptidyl peptidase-4 (DPPIV) inhibitor had been developed recently [60].
Nevertheless, none of these molecules reached market authorization so far. Unfortunately, 
a significant number of MCHR1 antagonists showed a cardiovascular risk involving human 
ether-a-go-go gene (hERG) potassium channel inhibition and QT prolongation. hERG blockers 
are associated with lethal arrhythmias known as torsade de pointes. Structural requirements, 
such as a positively charged group and at least one distal aromatic/hydrophobic region, for 
MCHR1 potency correlate with hERG inhibition. Efforts in designing MCHR1 antagonists 
with improved selectivity over hERG are undertaken by several pharmaceutical companies; a 
few candidates have progressed to clinical development [71].
4. Diagnostic imaging
It has been described that changes of expression of the MCHR1 are related to various dis-
eases, such as obesity, diabetes, gut inflammation, hydrocephalus, and depression. Thus, the 
MCHR1 seems to be a promising target for various clinical questions.
In the last decades, positron emission tomography (PET) has become a vital and versatile 
modality for modern medicine, as well as for applied medicinal research. At present, it 
belongs to the most sensitive methods for the purpose of molecular imaging [72]. However, 
the potential of nuclear molecular imaging and its capabilities strongly depends on the supply 
of potent and specific radiotracers for specific applications. Hence, the evaluation and devel-
opment of new highly affine and selective radioligands is an indispensable part to increase 
the scope of application for molecular imaging.
A PET tracer for the MCHR1 comprises several advantages for clinicians and patients as 
the in vivo monitoring and following of the hormone receptor status and related patholo-
gies. Moreover, it could support dose selection of MCHR1 antagonists in drug development 
[59] and would provide a deeper understanding of the involvement and distribution of the 
MCHR1. Therefore, specific MCHR1 imaging is of high clinical interest for status monitoring 
in endocrine pathologies such as obesity and diabetes.
As mentioned before, Borowsky et al. [51] presented the evaluation of the very potent MCHR1 
antagonist SNAP-7941, which contains a methyl ester (Figure 3(1)), making it suitable for 
radiolabeling introducing either a [11C]methyl moiety or a 2-[18F]fluoroethyl moiety. On this 
basis, two potential PET tracers for the visualization of the MCHR1 were developed so far: 
[11C]SNAP-7941 (Figure 3(2)) and [18F]FE@SNAP (Figure 3(3)) [73–77].
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The radiosynthesis of [11C]SNAP-7941 could be conducted in a conventional synthesis mod-
ule and consisted of a [11C]methylation of the precursor SNAP acid. The optimal reaction 
conditions were found to be 2 min reaction time in acetonitrile at ≤25°C reaction temperature 
using 2 mg/ml precursor and [11C]CH
3
OTf as a methylation agent. Under these conditions, 
2.9 ± 1.6 GBq (11.5 ± 6.4% at end of bombardment (EOB)) [11C]SNAP-7941 could be produced. 
Radiochemical purity always exceeded 99% [73]. The specific radioactivity for the preclinical 
in vivo evaluation was 108.2 ± 56 GBq/μmol at the end of synthesis (EOS) [74]. The full radio-
synthesis, purification procedure, and physiological formulation could be automated to guar-
antee a safe and reliable production. All quality control parameters were in accordance with 
the standards for human application [73]. In vitro binding assays on CHO-K1 cell membranes 
expressing the human MCHR1 and MCHR2, respectively, evinced high-binding affinity 
(Ki = 4.52 ± 0.7 nM for the MCHR1) and selectivity (Ki > 1000 nM for the MCHR2) of [11C]
SNAP-7941. The metabolic stability of [11C]SNAP-7941 in plasma and against liver micro-
somes and carboxylesterases was very high: no degradation in human plasma over 60 min; 
<10% degradation by liver microsomes (human and rat) over 60 min and no decomposition 
by porcine carboxylesterases. Interestingly, in rat plasma, [11C]SNAP-7941 was metabolized 
considerably: 50.4 ± 1% of intact compound were found after 60 min. The formation of a 
hydrophilic metabolite was observed. The plasma free fraction was found to be sufficient 
for imaging: f1 = 21.0 ± 1% in human plasma and even 32.4 ± 1% in rat plasma. The lipophi-
licity was in a range, where a passive diffusion through the BBB would be expectable: log 
D7.4 = 3.29. However, in the in vivo experiments in healthy rats, [11C]SNAP-7941 evinced to 
be a P-glycoprotein (P-gp) substrate, since after blocking with the P-gp inhibitor Tariquidar 
(TQD), the [11C]SNAP-7941-uptake in the brain raised 3–5 times [74].
Of note, Borowsky et al. [51] observed a significant reduction in food intake and body weight 
in rats after i.p. application of SNAP-7941. Knowing that drugs have to cross the BBB to 
reduce body weight via central mechanisms [70], it is quite surprising that [11C]SNAP-7941 
evinced to be a P-gp substrate.
Nevertheless, no metabolite was found in the rat brains of the baseline and TQD-pretreatment 
group [74].
The biodistribution experiments showed both uptake in kidneys and in intestines. On the basis 
of the conducted experiments, a specification of the major way of excretion was not possible.
Uptake in MCHR1 expressing organs (adrenals, pancreas, eyes, muscle, and ovary) could be 
observed. Low uptake was found in peripheral fat tissue of the healthy rats [74].
Due to the advantage of the longer half-life of fluorine-18 (110 min) compared with carbon-11 
(20 min), [18F]FE@SNAP, the [18F]fluoroethylated derivative of SNAP-7941 was developed as 
the second PET tracer for the MCHR1. Its radiosynthesis was challenging; no vessel-based 
approach succeeded. Only the preparation within a microfluidic device was successful, con-
sisting of the direct [18F]fluorination of the tosylated precursor (Tos@SNAP). Harsh reaction 
conditions had to be applied: high reaction temperature of 170°C and a short reaction time 
using an overall flow rate of 150 μl/min. Since the microfluidic device was not equipped 
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for purification steps, the crude reaction mixture was purified in a conventional synthesis 
module. The radiosynthesis as well as the purification and physiological formulation were 
automated to guarantee safe and reliable production. The radiochemical yield ranged between 
100 and 650 MBq, which was sufficient for every subsequent preclinical experiment. Specific 
radioactivity was 24.8 ± 12 GBq/μmol EOS. All quality control parameters were in accordance 
with the standards for human application [75].
[18F]FE@SNAP evinced high-binding affinity and selectivity to the MCHR1: Kd = 2.9 ± 2.5 
nM for the MCHR1; Ki > 1000 nM for the MCHR2. Similar to [11C]SNAP-7941, it is highly 
stable in human plasma (only 3.9 ± 4% metabolism after 120 min), against liver microsomes 
(<10% metabolism after 60 min) and porcine carboxylesterases (Km = 347.3 μM) and rapidly 
metabolized in rat plasma (completely after 120 min). The plasma-free fraction was lower 
(f1 = 12.6 ± 0.2%) than for [11C]SNAP-7941, but can still be considered high enough for imag-
ing. Compared with SNAP-7941, the lipophilicity was slightly higher: logD7.4 = 3.83 [76].
After IV administration of [18F]FE@SNAP into healthy and conscious rats, ex vivo autora-
diography of the brains evinced specific tracer uptake in the hypothalamic region and the 
ventricular system. In addition, preliminary small-animal PET measurements in healthy rats 
showed a high tracer uptake in the ventricular system (Figure 4) [77].
Figure 4. Exemplary small-animal PET/CT and PET and MR image of a rat brain with [18F]FE@SNAP. Rats were 
anesthetized by isoflurane. 25 min after [18F]FE@SNAP iv injection, vehicle (A) or 15mg/kg SNAP-7941 (B) were 
administered through the tail vein. 75 min after tracer injection, the rats were sacrificed. A significant reduction in tracer 
uptake could be observed after the administration of SNAP-7941.
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Biodistribution experiments showed—similar to [11C]SNAP-7941—uptake in kidneys as well 
as in the intestines. Uptake in MCHR1 expressing organs (adrenals, pancreas, eyes, muscle, 
and tongue) could be observed too [77].
So far, [11C]SNAP-7941 and [18F]FE@SNAP are the only described potential PET tracers for 
the MCHR1. Both proved high affinity and selectivity for the MCHR1; could be prepared in a 
reproducible and feasible way; evinced high metabolic stability in human plasma and against 
human and rat liver microsomes and showed specific uptake in preclinical in vivo experiments 
in healthy rats. Since the extent of MCHR1 expression in obese or diabetic rats is unknown, fur-
ther experiments with [11C]SNAP-7941 or [18F]FE@SNAP in obese and diabetic rats will show 
the applicability of the MCHR1 concept. Furthermore, the quantitative analysis and evalua-
tion of the preclinical data may provide high-impact predictive values upon further clinical 
application in PET imaging for diagnosis and further treatment of MCHR1-related diseases. A 
more detailed insight and better understanding of the involvement of the MCHR1 in various 
neurotransmitter systems can be obtained, which potentially provides the basis for the devel-
opment of novel pharmaceuticals and eventually, may serve as new working standard for the 
evaluation of the MCHR1 as a potential binding site of atypical antipsychotic drugs, using PET.
5. Conclusion
MCH was initially characterized as a factor mediating color change in teleost fish. In response 
to the environmental background, MCH causes a concentration of pigment in melanophores, 
thus producing a lighting of pigmentation and has the opposite effect of α-MSH, which causes 
darkening of fish pigmentation. This phenomenon is crucial for fish to camouflage themselves 
from predators.
Although MCH is expressed in human melanocytes too, it has not been shown to affect 
human pigmentation so far. In mammals, MCH operates as a neuropeptide and involvement 
of MCH/MCHR1 was reported in obesity and diabetes, and MCHR1 has also been related to 
depression, colitis, and hydrocephalus. Therefore, MCHR1 imaging is of high clinical interest 
for monitoring these pathologies and guide pharmacological interventions. Specific MCHR1 
PET tracers could serve as a useful tool for diagnostic imaging. So far, the first two PET tracer 
for the MCHR1, [11C]SNAP-7941, and [18F]FE@SNAP are evaluated in preclinical settings.
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